Red meat's side effects

According to many studies, joint pain can occur because of your diet.

The U.S. diet is full of highly processed food, which can produce an inflammation effect on the body. These foods include packed foods, sugar, and red meat, and according to scientists both may be the main reason why you experience joint pain.

A diet without processed food can help prevent chronic arthritis or joint pain, and according to many studies, it is suggested that diet consist mainly of plant bases, which help in the pain of knots.

For example, a 2015 study found that people who ate a diet rich in whole foods experienced a significant decline in their atrosis pain after just two weeks. Participants also reported having more energy and better physical operation until the end of the six-week study.

Moreover, findings by a 2017 study show that fibers can also play a role in preventing arthritis. Those who went on a diet rich in fiber reduced their risk of knot disease to 61 percent.

Foods that are high in fat and highly processed can change your bowel microbiotics, which may be the cause of a host of health issues. By contrast, plant-based foods that are rich in prebiotics and probiotics-can help diversify healthy intestine bacteria and reduce inflammation.

Now, new research by the Mayo Clinic Individual Medicine Center shows that your bowel microbima can predict whether or not you will develop rheumatoid arthritis.

The study, which was published in Genome Medicine magazine, revealed several features within the intestinal microbioma linked to a future prognosis of rheumatoid (RA) arthritis.

For context, RA is a chronic, inflammatory disorder that occurs when the immune system starts attacking its own tissues, including joints. Some symptoms of RA include rigidity, pain, and swelling at more than one knot, according to the Centers for Disease Control and Prevention.

Researchers propose that testing people's utero microbiotics can help them to find out if someone is at risk of being diagnosed later in life.

With further development, such proagnostic biomarketers can identify patients who will achieve early clinical improvement with a given therapy, thus saving spending and risking other therapies that are less likely to be effective”, said John M. Davis, author of research and clinical rheumatologist at the Mayo Clinic.